Key Details
Price
$14.76Annual ROE
34.67%Beta
0.32Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Oct 07, 2024Analyst ratings
Recent major analysts updates
08 Nov '24 HC Wainwright & Co.
Buy10 Oct '24 Oppenheimer
OutperformScreeners with OKUR included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
OnKure Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
OnKure Announces New Date for Upcoming Investor Call
OKUR
globenewswire.com25 November 2024
Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OKUR
globenewswire.com01 November 2024
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET
FAQ
- What is the primary business of OnKure Therapeutics?
- What is the ticker symbol for OnKure Therapeutics?
- Does OnKure Therapeutics pay dividends?
- What sector is OnKure Therapeutics in?
- What industry is OnKure Therapeutics in?
- What country is OnKure Therapeutics based in?
- Is OnKure Therapeutics in the S&P 500?
- Is OnKure Therapeutics in the NASDAQ 100?
- Is OnKure Therapeutics in the Dow Jones?
- When does OnKure Therapeutics report earnings?
- Should I buy OnKure Therapeutics stock now?
What is the primary business of OnKure Therapeutics?
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
What is the ticker symbol for OnKure Therapeutics?
The ticker symbol for OnKure Therapeutics is NASDAQ:OKUR
Does OnKure Therapeutics pay dividends?
No, OnKure Therapeutics does not pay dividends
What sector is OnKure Therapeutics in?
OnKure Therapeutics is in the Healthcare sector
What industry is OnKure Therapeutics in?
OnKure Therapeutics is in the Biotechnology industry
What country is OnKure Therapeutics based in?
OnKure Therapeutics is headquartered in United States
Is OnKure Therapeutics in the S&P 500?
No, OnKure Therapeutics is not included in the S&P 500 index
Is OnKure Therapeutics in the NASDAQ 100?
No, OnKure Therapeutics is not included in the NASDAQ 100 index
Is OnKure Therapeutics in the Dow Jones?
No, OnKure Therapeutics is not included in the Dow Jones index
When does OnKure Therapeutics report earnings?
The date for OnKure Therapeutics's next earnings report has not been announced yet
Should I buy OnKure Therapeutics stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions